The angiogenic switch, a rate-limiting step in tumor progression, has already occurred by the time most human tumors are detectable. However, despite significant study of the mechanisms controlling this switch, the kinetics and reversibility of the process have not been Collectively, these data demonstrate that the angiogenic phenotype in tumors is malleable and can spontaneously revert to the non-angiogenic phenotype in a population of human tumor cells.
Introduction
In cancer, a tumor's switch to angiogenesis is a rate-limiting step in its progression from microscopic to macroscopic size (1) . As a result, small, occult tumors are a common finding on autopsy of individuals who die of non-neoplastic causes (primary studies summarized in (2) ). In contrast, the converse finding-of tumors that switch off angiogenesis and thus cease macroscopic growth-is rare (2) . Nevertheless, there are a limited number of reports of tumors that cease macroscopic growth, suggesting that such a reversion of the angiogenic switch may occur (3, 4) .
Regulation of angiogenesis is typically viewed as a switch whose state is governed by the relative local concentration of angiogenesis stimulators and inhibitors. The switch metaphor is common in the field because of the strong biphasic nature of angiogenesis. In experimental models of pathological conditions it is rare to observe small, stepwise accumulation of additional vessels. Rather it is common to observe that once angiogenesis has been initiated, vessel growth proceeds throughout the pathologic process. In addition, variation in intensity of angiogenesis has been observed, and appears to be a major rate-limiting factor in tumor growth. For example, substantial variation in microvessel density is observed throughout tumors, with regions exhibiting the highest density predicting the overall growth rate of a tumor, metastatic status, and patient survival (5) (6) (7) .
In contrast to the tumor as a whole, we and others have shown that individual tumor cells can exhibit significant variation in their ability to induce angiogenesis. For example, when individual cell clones derived from a primary human liporsarcoma are implanted in immunocompromised mice, the timing of the transition to macroscopic growth varies from 7 to >160 days (8) . In addition, several commercially available tumor cell lines, originally derived from human tumors that were macroscopic in size, exhibit extended periods of pre-angiogenic growth, ranging from few weeks, to years, to the lifespan of the animal (9) . However, an experimentally-induced increase in the angiogenic output of these tumors (e.g. by transfection with VEGF (10, 11)), results in early and rapid macroscopic growth. Similarly, alterations occurring during extended evolution of dormant tumors in mice can result in increased net angiogenic output. In at least one system, this was accompanied by a decrease in expression of angiogenic inhibitors (e.g. thrombospondin-1), rather than an increase in angiogenic stimulators (e.g. VEGF) (12). Importantly, in vitro growth rates for the angiogenic sublines, derived from the non-angiogenic parental lines, in all of these experiments did not differ significantly from the growth rate of non-angiogenic sublines. These findings exclude differences in cell division rate as a mechanism for the observed differences in macroscopic growth.
Finally, experiments in which angiogenic cells were admixed with non-angiogenic cells prior to inoculation in mice have demonstrated that even a minority of pro-angiogenic cells is sufficient to induce growth (and metastasis) in the entire tumor (11). Non-transformed (i.e. stromal) cells have also been shown to play a critical role in the induction of angiogenesis in some tumors (13). These observations lead to the notion that the angiogenic switch may be an ensemble property comprised of contributions from all the cells in the tumor, rather than an obligate property of only the tumorigenically transformed cells in a tumor (10) . Therefore, it is possible that individual tumor cells, although derived from an angiogenic tumor, may not possess the angiogenesis-inducing potential of that tumor. We sought to test that possibility by serial in vivo passage, cloning, and quantitative analysis of the growth phenotypes of such individual tumor cells. In addition to assessing the stability of the switch to an angiogenic phenotype in individual cells, these experiments allowed us to assess the nature of the events that lead to the angiogenic switch, and determine that it is not comprised of a single step. 
Materials and Methods
Generation of single cell clones. Angiogenic (Clone -9) and nonangiogenic (Clone -4) cell lines were established from the SW-872 cell line as previously described (8, 14) . For the first in vivo passage, a new cell line (Clone -9#2) was generated following subcutaneous inoculation into a SCID mouse. Subclones with similar growth rates were prepared for subsequent in vivo passage from monolayers of the Clone -9#2 cell line following limiting dilution ( 
.
Real-time RT-PCR.
RT-RT-PCR analysis was performed in triplicate on 20 ng cDNA prepared using Thermoscript RT-PCR system using validated Taqman gene expression assays (Applied Biosystems, Foster City, CA). Following outlier exclusion (samples with a CT standard deviation > 0.3), angiogenic and non-angiogenic samples were compared by ΔΔCT using GADPH as endogenous control.
Statistical analysis. Time to palpable tumor for the angiogenic and non-angiogenic cells was compared using the Kaplan-Meier method, with survival curves compared using log-rank test (16) , and confidence intervals determined using Greenwood's formula (15) . For a subset of tumors, we compared the median time from initial palpation to a size of 500 mm 3 using the 
Results
In vivo growth of angiogenic and non-angiogenic human liposarcoma single-cell derived clones.
We previously described an animal model of human liposarcoma, based on the phenomenon that all human tumors are comprised of angiogenic and non-angiogenic tumor cell populations (8) . Specifically, two single cell clones were derived from the original tumor population: one displayed angiogenic properties (Clone-9) and one was non-angiogenic (Clone-4). Here, we characterize the in vivo growth potential of these clonal populations in detail using a xenograft model (Figure 1 ). We observed that 100% of SCID mice (n=13) inoculated with To better understand the nature of the process underlying the switch to the angiogenic phenotype (and exponential tumor growth) we examined the distribution of switch times ( Figure   1C-D) . If the process were clock-like (e.g. results from local accumulation of a pro-angiogenic factor to a pre-determined threshold), escape times would be distributed in a Gaussian fashion.
In contrast, if the process is governed by events (e.g. mutations or other heritable regulatory events), then escape times will follow a multistage model curve of the form (18, 19) .
Comparing these models using AIC (Akaike Information Criterion) shows that in our experimental model there is greater evidence for the mutation model (evidence ratio >10 Early-growing and revertant clones did not differ in proliferation in vitro or in vivo, but did exhibit differences in expression of angiogenic regulators.
We then sought to determine the underlying mechanism governing the in vivo properties of the early-growing and revertant clones. We first examined whether the two types of clones possessed different in vitro growth kinetics. We compared the in vitro proliferation potential of two revertant clones and three early-growing clones from the 2 nd in vivo passage and generated in vitro growth curves ( Figure 5 ). Importantly, we did not observe a significant difference in growth rates in vitro between the two types of clones. We also compared the in vivo growth rates via PCNA staining of dormant and exponentially growing tumors. While there was no significant difference in the fraction of nuclei that stained positive for PCNA (Supplemental Since we observed no differences in in vitro or in vivo proliferation rates or the ability to form colonies in semisolid media between the early-growing and revertant clones, we postulated that there may be a difference in net angiogenic output between the two clone types, as had occurred in the parental lines. In order to begin to test this hypothesis we examined these clones for expression of the angiogenic stimulator VEGF and the angiogenesis inhibitor revertants suggest that the cause of the revertant phenotype is a decrease in net angiogenic activity. However, expression data alone cannot firmly establish that the change in tumor growth kinetics results from lower angiogenesis-inducing activity in the revertant clones than the early-growing "angiogenic" cell lines. Therefore, to determine whether the clones actually exhibited different angiogenic output, which could account for their differential growth properties in vivo, we performed the endothelial migration assay, a well-validated surrogate for the angiogenic response (21) . This allowed us to directly measure the net angiogenic output of the revertant and "angiogenic" clones. The ability of two early-growing (9-1 and 9-29) and two revertant clones (9-2 and 9-10) to induce the migration of human microvascular endothelial cells (HMVECs) were compared in a modified Boyden chamber assay. We observed the early- 
growing "angiogenic" clones had induced 3-4-fold more migration than the revertant clones (P<0.05 by ANOVA, Figure 6D ). Taken together with the expression data and the previous findings that Clone -9 was more angiogenic than Clone -4, the data indicate that reversion from the early-growing, angiogenic phenotype to dormancy is mediated by a decrease in net angiogenic output.
Differences in in vitro gene expression were observed between angiogenic and non-angiogenic clones.
In order to obtain more comprehensive insight into the molecular differences between angiogenic and revertant cell lines, we performed global gene expression profiling. Two independent angiogenic and three independent non-angiogenic cell clones from the second cycle of cloning (clones 9-2, 9-10 vs. 9-28, 9-29, 9-37, respectively) were selected and expression of RNA transcripts was measured using Agilent microarrays. Differences in expression of the top 31 genes were confirmed by real-time RT-PCR ( Figure 7) . Clustering of upregulated genes from either the angiogenic clone dataset or the revertant clone dataset around distinct chromosomal locations was not observed (see Supplemental Figure 2 ).
Of the genes upregulated in angiogenic clones, the top canonical pathways represented as determined by Ingenuity Pathway Analysis were acute response phase signaling, ephrin receptor signaling, axonal guidance signaling, the complement system and relaxin signaling (Supplemental Figure 3A) . Other pathways significantly overrepresented included PPAR signaling, molecular mechanisms of cancer, and sphingolipid metabolism. In revertant clones the top canonical pathways represented were antigen presentation pathway, dendritic cell maturation, autoimmune thyroid disease signaling and allograft rejection signaling (Supplemental Figure 3B) . Other pathways significantly overrepresented included semaphorin signaling in neurons, NFκB signaling and death receptor signaling. 
Discussion
Our studies provide clear evidence that the angiogenic switch is reversible at the cellular level. While the findings in this report are specific to the liposarcoma cell lines used, there is reason to believe that dormancy and angiogenesis may also exhibit the same plasticity in other tumor types though not necessarily by the same mechanisms (34) . Specifically, we demonstrate the striking finding that a single cell clone that forms angiogenic tumors can also give rise to cells that are incapable of inducing angiogenesis. Importantly, this indicates that even in actively growing tumors, a significant fraction (perhaps a majority) of tumor cells are non-angiogenic. Importantly, we observed no difference in growth rate or anchorageindependent growth in angiogenic vs. non-angiogenic tumors. These findings demonstrate that pro-angiogenic events can exist independent of changes that affect cell growth rate, differentiation, and the transformed state. Further, the delay in growth for non-angiogenic tumors demonstrates that pro-angiogenic events are required for macroscopic tumor growth, and the kinetics of that delay suggest that two such changes were necessary in this model. This notion is bolstered by the observation that a significant fraction (21%-52%) of clones from angiogenic tumors exhibited an intermediate phenotype in which a fraction of tumors exhibited growth indistinguishable from angiogenic clones and a fraction exhibited growth indistinguishable from non-angiogenic clones. One possible explanation for such behavior would be that the initiating cell clone had lost one, but not all of the changes necessary to become angiogenic. As this clone was then expanded, additional changes would result in some subpopulations that were angiogenic and some that were non-angiogenic. This phenotype was then manifest when these cell populations were injected in vivo.
While there are inherent limitations to studying expression changes in cell culture to explain complex in vivo phenomena, the fact that our analysis identified several genes previously demonstrated to be critically involved in regulating angiogenesis indicates that at least a portion of these changes also occur in vivo. In this study we observed several protein thrombospondin-1. Interestingly, we did not observe a difference in VEGF expression that could account for the differences in growth that we noted. However, one caveat to these studies is that VEGF expression that we observed in vitro may not completely reflect VEGF expression in the tumor implant. For example, VEGF might be upregulated by the hypoxic environment in the nascent tumor or stimulated in the tumor microenvironment. Importantly, however, this effect is likely to be similar for both the angiogenic and nonangiogenic tumors, and may even be accentuated by the extended period of hypoxia experienced by the nonangiogenic tumors. In our broader examination of the transcriptome of angiogenic and nonangiogenic cell types, additional differences in gene expression were observed. Many of the most highly upregulated genes in revertant clones have been previously implicated in tumor progression and/or metastasis (35) (36) (37) (38) (39) (40) (41) (42) (43) This might suggest that upregulation of these genes in revertant clones is a secondary effect of the overall decrease in angiogenesis induced by these cells and that the primary determinants of the reduced angiogenic stimulus remain to be determined. First, there are indications that the threshold for the initiation of angiogenesis is higher than that for its continuation. Processes such as pericyte dissociation and degradation of basement membrane (with its associated inhibitors) once accomplished need not be repeated for vessels to be extended. Second, once a tumor has begun to expand there is more (angiogenic factor producing) tumor mass available to supply angiogenic factors (such as VEGF, HGF etc.) to a given region of the tumor periphery. Thus for a tumor whose radius has expanded 2-fold, the fraction of angiogenic cells can be reduced by a similar amount without compromising the ability of the tumor to induce blood vessels at its periphery. Indeed, once established, a tumor can expand even if a fraction of the periphery of the tumor has become net non-angiogenic. In that case, the tumor will not expand in all directions, but will become irregular in shape as only the angiogenic portion of the tumor expands.
The specific molecular basis for the change of a tumor cell from the angiogenic to nonangiogenic phenotype and its subsequent reversal is currently unclear. There is evidence in the literature that the angiogenic phenotype can be regulated by mutations to specific oncogenes Angiogenic/revertant fold difference in cDNA Figure 7 on October 27, 2017. © 2014 American Association for Cancer Research.
